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EPIGENETIC EVENTS SUGGEST A DISTINCT MOLECULAR PATHOGENESIS IN 
BRAF-ASSOCIATED PAPILLARY THYROID CANCER.  
 
Ogechukwu Eze, Lee Starker, William Long, Robert Udelsman, Peyman Björklund, and 
Tobias Carling. Department of Surgery, Yale University School of Medicine, New 
Haven, CT, USA. 
 
Papillary thyroid cancer (PTC) associated with a somatic V-raf murine sarcoma viral 
oncogene homolog B1 (BRAF) V600E mutation has been associated with a more 
aggressive phenotype (i.e. extrathyroidal extension, lymph node metastasis, high TNM 
stage and recurrence) than those with wildtype (WT) BRAF. The underlying molecular 
mechanism for this association is incompletely clarified. Epigenetic alterations, such as 
DNA methylation participate with genetic abnormalities to cause altered patterns of gene 
expression and/or function leading to oncogenesis. Using a quantitative, genome-wide 
approach to evaluate the PTC DNA methylome, we identified a distinct DNA 
methylation profile in BRAF-associated PTC. This represents the first, unbiased, 
systematic, quantitative genome-wide evaluation of DNA methylation alterations in PTC. 
 
A distinct DNA methylation profile was noted in BRAF V600E PTC versus BRAF WT 
PTC. Twenty-four genes were significantly hypermethylated in BRAF V600E PTC 
versus BRAF WT (p<0.005 for all). Genes frequently and significantly hypermethylated 
in BRAF V600E PTC included those involved in transcriptional regulation and cell cycle 
control such as CDKN2B/p15, RASSF1A and CD6. 25 BRAF V600E PTC and 25 BRAF 
WT PTC were used for validation of the methylation profile of RASSF1 and analysis of 
its gene expression. One of two CpG islands in the RASSF1A promoter was differentially 




BRAF WT PTC respectively. In addition, 92% (n=23) of the BRAF V600E tumors were 
hypermethylated at this CpG island, compared to 12% (n=3) of the BRAF WT tumors. 
Expression of RASSF1A was decreased in BRAF V600E PTC relative to expression in 
BRAF WT PTC.  
 
The DNA methylation profile of PTC correlates with BRAF mutational status, 
underscoring its importance in PTC development. The molecular mechanism of the more 
aggressive phenotype of BRAF V600E PTC may be related to aberrant DNA methylation 
of genes involved in transcriptional and cell cycle control. Functional studies assessing 
the effect of azanucleoside, a demethylating agent on RASSF1A gene expression may 
further determine a cause-effect relationship. Furthermore, conducting such functional 
experiments in BRAF V600E PTC and BRAF WT PTC cell cultures would be critical in 
assessing the possibility of clinically applying a demethylating agent to treatment of 
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Thyroid carcinoma is the most common endocrine malignancy. Papillary thyroid 
cancer (PTC) accounts for over 90% of thyroid malignancies1. With improved diagnostic 
techniques, papillary thyroid carcinoma is identified much more frequently than in the 
past2. Currently, the majority of patients present with a thyroid nodule and are often 
asymptomatic. Symptomatic patients, however, may present with concomitant vocal cord 
dysfunction or subglottic/tracheal mass, recurrent disease in the central compartment, 
symptomatic disease with voice changes, dyspnea, hemoptysis or dysphagia, and finally, 
patients with documented invasive disease based on pre-operative imaging3. More 
papillary thyroid cancers are diagnosed as microcarcinomas, therefore molecular methods 
of detecting aggressive disease will aid in treatment planning.  
 
Genetic Alterations in Papillary Thyroid Cancer 
The majority of genetic alterations in thyroid cancer exert their oncogenic actions 
at least partially through the activation of the RAS/mitogen-activated protein 
kinase/Extracellular signal-regulated protein kinase (MAPK/ERK) pathway. Constitutive 
activation of the MAPK/ERK pathway leads to tumorigenesis by upregulating cell 
division and proliferation4. Activation of this pathway is a common and important 
mechanism in the genesis and progression of human cancers. When constitutively 
activated, the MAPK/ERK pathway leads to tumorigenesis4. Alterations of RET/PTC, 






The RAS/mitogen-activated protein kinase (MAPK)/Extracellular signal-regulated 
protein kinase (ERK) pathway  
The mitogen-activated protein kinases are proline-targeted serine/threonine 
kinases involved in the RAS/mitogen-activated protein kinase (MAPK)/Extracellular 
signal-regulated protein kinase (ERK) signal transduction pathways that regulate nuclear 
gene transcription in response to changes in the cellular environment (Turjanski, 2007).  
The MAPK/ERK pathway is activated by a GTP-bound active RAS protein, 
which is activated by binding of an extracellular growth factor to a growth factor receptor 
in the cell membrane causing receptor phosphorylation and interaction with a nucleotide 
exchange factor, SOS, and inactive GDP-bound RAS. Activation of RAS results in a 
conformational change that allows it to interact with RAF, a serine-threonine kinase and 
bring it to the plasma membrane. RAF phosphorylates and activates MAPK/ERK kinase, 
which in turn phosphorylates ERK kinase. Phosphorylated ERK translocates to the 
nucleus, targeting transcription factors.  
Activation of the RAS/MAPK/ERK kinase signal transduction pathway is 
involved in transcription of nuclear oncogenes such as MYC and FOS, and cell cycle 
components such as cyclin D1. This pathway controls cellular functions involved in 











Figure 1.  The mitogen-activated protein kinase (MAPK)/Extracellular signal-regulated 














RET proto-oncogene encodes a cell membrane receptor tyrosine kinase. Ligands 
of the kinase are of the glial-cell line-derived neurotrophic factor (GDNF) family which 
cause the receptors to dimerize upon binding, leading to auto-phosphorylation of tyrosine 
residues and initiation of the MAPK/ERK pathway signaling cascade8. High expression 
of RET in parafollicular C-cells of the thyroid gland are consistent with its role in 
development of neural crest-derived cell lineages. This high expression of RET does not 
occur in thyroid follicular cells, however, RET activation in these cells occurs by fusion 
of the 3’ tyrosine domain of RET to the 5’ portion of constitutively expressed genes.  
The most common RET/PTC rearrangements seen in PTC are RET/PTC1 (fusion 
with H4 gene) and RET/PTC3 (fusion with NCOA4 gene). Prevalence of RET/PTC 
rearrangements in PTC is greatest in populations exposed to radiation (60–70%). In the 
general population, the prevalence is higher in children6. Activation of RET/PTC results 
in downregulation of thyroglobulin and sodium iodide importer genes, which are thyroid 
specific, and cell differentiation. Wildtype RET/PTC and truncated forms of RET/PTC 
activate a number of other pathways, including the PI3K/AKT pathway, contributing to 
its biological activity9.  
 
BRAF 
 Mutations of BRAF, a serine-threonine kinase and downstream signaling 
molecule of RAS and RET, are potent activators of the MAPK/ERK pathway4,10. These 
missense mutations of the BRAF gene, located on chromosome 7, occur in the kinase 




substitution of valine to glutamic acid (V600E) accounting for 80-90% of BRAF 
activating mutations6,11. The V600E mutation is thought to mimic phosphorylation in the 
activation segment of BRAF by inserting a negatively charged residue adjacent to an 
activating phosphorylation site4.  
 BRAF V600E occurs as a sporadic mutation in thyroid cancer11,12 and is restricted 
to papillary and anaplastic or poorly differentiated carcinomas13. Prevalence of the 
mutation is reported in papillary thyroid cancer at 35-40%, with a significantly higher 
prevalence in males than females11. The rate of BRAF mutation in PTC is the second 
highest to that in melanomas (60%) and is much higher than other cancers such as 
colorectal adenocarcinomas (5–10%) and lung cancers (1.8%)11. BRAF V600E correlates 
with poorer clinicopathologic outcomes defined as extrathyroidal extension, lymph node 
metastasis, and advanced tumor grade (III/IV) at presentation, and is prognostic of tumor 
recurrence14,15.  
Although not confirmed by similar studies12, 38% of papillary thyroid tumors 
showed RET/PTC rearrangement11, contrary to reports that BRAF V600E mutation is 
does not occur with RET/PTC or RAS mutations in cancer12. The low oncogenic 
potential of both BRAF and RET/PTC1 suggest that both mutations occurring in the 
same pathway are not necessarily redundant, but may cooperate in papillary thyroid 
tumorigenesis. Indeed, RET/PTC1 and RAS mutations have been shown to 






Activating mutations of the three RAS oncogenes (H-RAS, K-RAS, and N-RAS) 
occur in thyroid tumors, however, their prevalence depending on histology of the tumors 
has been controversial16. Early studies demonstrated that RAS mutations were more 
frequent in follicular tumors than papillary thyroid cancers, in addition to different 
patterns of mutations occurring in the two types. Indeed, mutations in up to 50% on 
microfollicular adenoma further supported the idea that RAS oncogene activation was an 
early event in follicular thyroid tumorigenesis. More recent studies have reported varying 
incidences of RAS mutations in thyroid tumors (0-50% in PTC, 0-85% in adenomas, 14-
62% in FTC, and 0-60% in anaplastic carcinomas). Some investigators find no 
correlation between RAS mutation isoforms and tumor pathology, while others report a 
higher frequency of mutations in codon61 of H-RAS and N-RAS in FTC and poorly 
differentiated carcinomas.  
The molecular pathogenesis of PTC thus remains incompletely clarified. With 
respect to gene alterations, papillary thyroid cancers have relatively low rates of loss of 
heterozygosity, with no specific region displaying a particularly high prevalence when 
compared to follicular thyroid cancers17. Like RET, BRAF or RAS mutations, other 
molecular alterations are thought to be essential for the induction of papillary thyroid 
cancer. Epigenetic events are very likely to contribute to significant variation in gene 
expression profiling, phenotypical features, and biologic characteristics seen among 
papillary thyroid carcinoma18. 
 
 
Familial Nonmedullary Thyroid Cancer 
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Although mostly sporadic, there is some evidence for a familial form of 
nonmedullary thyroid cancer (NMTC), which includes PTC, not associated with known 
Mendelian syndromes. Familial nonmedullary thyroid cancer (FNMTC) is thought to 
cause a more aggressive disease marked by younger age at presentation, multifocality, 
local invasion, lymph node metastasis and tumor recurrence. Linkage analysis data is 
limited by the small size and inconsistent inclusion criteria of the studies performed, but 
point to a polygenic mode of inheritance in FNMTC. Perhaps the most important result of 
these studies is the exclusion of several genes, namely the adenomatous polyposis coli 
(APC), phosphate and tensin homolog (PTEN), thyroid-stimulating hormone receptor, 
rearranged during transfection (RET), tropomyosin receptor kinase, hepatocyte growth 
factor receptor (MET), TRKA, JUNB, and BRAF genes. 
 
Epigenetics mechanisms involved in tumorigenesis 
Epigenetic silencing of regulatory genes is part of the global genomic alterations 
in cancer that alter pathways relevant to stem cell growth and differentiation. Epigenetic 
silencing mechanisms include covalent modifications of chromatin, DNA cytosine 
methylation, non-coding RNAs, and nucleosome remodelling19. It has been proposed that 
epigenetic abnormalities may play a seminal role in the earliest steps in tumorigenesis20-
23. Epigenetic changes may act in concert with genetic changes resulting in 
tumorigenesis, because they are mitotically heritable. The high degree of mitotic stability 
of silencing plus the progressive nature by which it is achieved makes pathological 
silencing of growth controlling, and other genes essential to carcinogenesis.  
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 Patterns of DNA methylation are linked to gene expression; for example, 
methylation in a gene promoter region generally correlates with a silenced gene24. DNA 
methylation, the DNA methyltransferase (DNMT) catalyzed addition of methyl group to 
cytosine ring is restricted to cytosines that precede a guanosine in the DNA sequence (the 
CpG dinucleotide) in humans and other mammals24. The distribution of CpG 
dinucleotides in the genome is unusually asymmetric, occurring in small clusters called 
“CpG islands”. The CpG islands are often in promoter regions of genes and are usually 
unmethylated regardless of the transcriptional state. This highlights the importance of 
DNA methylation for gene expression, especially in transcriptional silencing24.  
Aberrant DNA methylation plays a strong role in tumorigenesis. Global 
hypomethylation of intergenic CpG dinucleotides and regional hypermethylation of CpG 
islands in promoter regions are characteristic hallmarks of many cancers23.  The impact of 
hypermethylation on tumorigenesis is further illustrated by the silencing of multiple 
tumor suppressor genes, thereby contributing to the hallmarks of carcinogenesis which 
include evading apoptosis (P53, p14ARF, BNIP3, Caspase-8), insensitivity to antigrowth 
signals (p16INK4a, miR-124a), sustained angiogenesis (TIMP3, TSP1), limitless 
replicative potential (hTERT), and tissue invasion and metastasis (E-cadherin, LIMS2). 
 Transcriptional silencing is also a result of chromatin compaction due to 
convergence of DNA methylation and histone modifications. Methylated DNA recruits 
methyl-binding proteins (MBDPs), which have methyl-CpG-binding domains (MBD), to 
hypermethylated DNA. MBDPS also associate with histone deacetylases, resulting in 
chromatin remodeling and gene silencing. In addition to these mechanisms of silencing, 
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histone methyltransferase (HMTs) repress transcription by methylation of lysine 9 of 
histone 3 (H3K9) or lysine 27 of histone 3 (H3K27).  
The influence of epigenetic events on tumorigenesis is well illustrated the 
evolution of colon cancer, in which risk factors for common cancers such as aging and 
inflammation are shown to cause expansions in either normal colon epithelial stem cells 
or precursor cells derived from them. Epigenetic gatekeepers such as cyclin-dependent 
kinase inhibitor 2A (CDKN2A/p16), secreted frizzled-related protein (SFRP), GATA-
binding protein 4 and 5 (GATA-4 and -5), and adenomatous polyposis of the colon 
(APC) prevent early tumor progression in colon cancer. Normal epigenetic modulation of 
these gatekeeper genes allows them to prevent stem/precursor cells from becoming 
immortalized during periods of chronic stresses and renewal pressures on cell systems. 
APC is a classically mutated tumor suppressor gene in colon cancer, which is also 
inactivated by epigenetic mechanisms25. Epigenetic silencing of one allele serves as a 
second-hit in Knudson’s hypothesis for tumor suppressor gene inactivation when paired 
which mutations on the other allele20.  
 Like APC, loss of p16 can be epigenetically mediated, permitting expanding cells 
to develop genomic instability26,27 and further epigenetic gene-silencing events28. Its loss 
is seen in subsets of pre-invasive stages of colon and other cancers28. Finally, GATA-4 
and -5 transcription factor genes important for both embryonic gastrointestinal epithelial 
development and for maturation in adults are epigenetically silenced in about half of all 
the pre-invasive and invasive lesions for colon cancer29. This can hamper differentiation 
and promote precursor cell expansion.  
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 The wingless-type MMTV integration site (Wnt) pathway activation also 
illustrates how multiple epigenetic events may act in concert to affect a single-cell 
pathway. Inappropriate silencing of these genes leads to abnormal activation of the Wnt 
pathway, which plays a canonical role in colon tumorigenesis22. These genes are 
independently affected by epigenetic events but result in Wnt activation. Four genes in 
the SFRP family encode proteins that antagonize the action of the Wnt ligand at the cell 
membrane are hypermethylated simultaneously in the majority of pre-invasive lesions for 
colon cancer.  Upregulation of the survival protein Sirtuin 1 (SIRT1) also results in Wnt 
pathway activation. SIRT1 is upregulated as a result of loss of the transcription factor 
hypermethylated in cancer 1 (HIC1) via hypermethylation in early pre-invasive lesions in 
colon cancer as well as other types of cancer22. Loss of HIC1 also results in additional 
gene silencing events as well as downregulation of tumor protein 53 (p53).  
 Loss of DNA methylation results in weakening of transcriptional repression in 
normally silent regions of the genome resulting in harmful expression of inserted or 
normally silenced genes, and loss of functional stability of chromosomes. It has been 
established that covalent histone modification is linked to DNA methylation. Cytosine 
methylation attracts methylated DNA-binding proteins and histone deacetylases to 
methylated CpG islands during chromatin compaction and gene silencing30,31. In addition 
to epigenetic modification of transcriptional start sites, there is evidence for more global 
changes in chromatin structure. For instance, there is an overall decrease in the 5-
methylcytosine content of cancer genomes that is reflected as hypermethylation in CpG 
islands32. The consistently observed hypermethylation is due to a change in 5-
methylcytosine distributions rather than an overall increase in total amount of 
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methylation. It has also been observed that large stretches of DNA can become 
abnormally methylated in cancer.  
 
Epigenetics of papillary thyroid cancer 
Quantitative analysis of promoter hypermethylation in thyroid cancer has 
involved RASSF1A, TSHR, RARβ2, DAPK, S100, p16, CDH1, CALCA, TIMP3, TGF-
β, and GSTpi33. Hypermethylation of 2 or more markers (RASSF1A, TSHR, RARβ2, 
DAPK, CDH1, TIMP3, TGF-β) was detectable in 25% of thyroid hyperplasias, 38% of 
adenomas, 48% of thyroid cancers, and 100% of cell lines. Rank correlation analysis of 
marker hypermethylation suggests that a subset of the markers were hypermethylated in 
concert, which may represent a thyroid-specific regulatory process33. Additionally, a 
positive correlation was observed between BRAF mutation and RARβ2, and a negative 
correlation between BRAF mutation and RASSF1A33.  
Investigation of DNA methylation in PTC has been predominantly restricted to 
individual candidate tumor suppressor genes and genes known for their role in thyroid 
function, using locus specific non-quantitative methods. BRAF, RASSFIA, TSHR, 
ECAD, NIS-L, ATM, DAPK, SLC5A8, TIMP3, and RARβ2 have been analyzed for 
DNA methylation. Promoter hypermethylation of TSHR, NIS-L, ATM, and ECAD has 
been demonstrated in 34-59%34,35, 22%, 50%, and 56% of patients with papillary thyroid 






Thyroid-stimulating hormone receptor (TSHR) and sodium iodide symporter (NIS) 
 TSHR stimulates several key steps in thyrocyte concentration of iodine, including 
uptake by NIS and oxidation before incorporation into thyroglobulin by thyroid 
peroxidase34. The methylation status of the NIS and TSHR promoter regions are 
important because these genes are specific to the thyroid may play a role in the uptake of 
iodine and normal cellular function35. Promoter hypermethylation resulting in decreased 
expression of TSHR and NIS may result in a decreased ability to concentrate iodine, 
rendering ablative doses of 131I ineffective35. Promoter hypermethylation of TSHR is 
reported in 34-59%34,35 of patients with papillary thyroid cancer. NIS mRNA expression 
has been shown to be decreased in thyroid cancers35,36, and this has been proposed to be 
secondary to methylation of the promoter region35,32. The NIS-L region within the 
promoter was shown to be hypermethylated in 22% (7/32) of patients with papillary 
thyroid cancer35, but was not methylated in surrounding histologically benign tissue.  
 
E-cadherin (ECAD) 
 E-cadherin complexes with catenins to promote Ca2+-dependent, homotypic cell-
to-cell adhesion and to establish normal epithelial tissue architecture37. Disruption of the 
E-cadherin/catenin complex contributes to tumor metastasis, and decreased expression of 
E-cadherin is observed in advanced stage, poorly differentiated carcinomas37. Promoter 
hypermethylation has been demonstrated in multiple human cancers, including papillary 





Ataxia telangiectasia mutated (ATM) 
 ATM is a member of the phosphatidylinositol 3-kinase family of proteins that 
respond to DNA damage by phosphorylating key substrates (p53, BRCA1) involved in 
DNA repair and/or cell cycle control38-40. Hypermethylation of ATM promoter was 
observed in 50% (16/32) of patients with papillary thyroid cancer analyzed35 
 
Apical iodide transporter (AIT) 
The thyroid apical iodide transporter AIT encoded by the SCL5A8 gene has been 
defined as a sodium-coupled transporter of short-chain fatty acid. It is thought that AIT 
may be involved in the passive transport of iodide from thyrocyte to the follicle 
lumen41,42. Expression of SCL5A8 is decreased in thyroid cancers compared to other 
iodide transporters41, and is expressed abundantly in colon cancer, functioning as a tumor 
suppressor gene. Silencing of SLC5A8 occurs by promoter hypermethylation in about 
50% of colon cancer cell lines and primary colon cancers. Decreased expression of 
SLC5A8 observed in classical variant of papillary thyroid cancer is linked to 
hypermethylation of exon 1 of the gene42.  
Hypermethylation occurred in 33% (76/231) of PTC and was associated with 
extrathyroidal invasion (40%) and multifocality (40%)43. This epigenetic event is thought 
occur at a later stage in papillary thyroid cancer and specific of the classical variant, 
therefore may be secondary to other genetic alterations occurring selectively in the tumor 
type42. Indeed, SLC5A8 and BRAF discriminate the classical variant PTC, supporting the 
argument. In addition, a strong association between low SLC5A8 expression and the 
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presence of BRAF V600E42 or advanced clinicopathologic features43 suggests a link in 
the progression to more aggressive papillary thyroid cancer. 
 
The tissue inhibitor of metalloproteinase 3 (TIMP3)  
TIMP3 is one of 4 tissue inhibitors of metalloproteinase thought to inhibit growth, 
angiogenesis, invasion, and metastasis in several human cancers43,44. TIMP3 inhibits 
vascular endothelial factor (VEGF)-mediated angiogenesis by blocking the binding of 
VEGF to VEGF receptor-2, thereby inhibiting downstream signaling and angiogenesis44. 
Promoter hypermethylation, and downregulation of TIMP3 expression is observed in 
various human cancers43,45-47. Hypermethylation in PTC occurred in 53% of tumors 
analyzed and was associated with extrathyroidal invasion (38%), lymph node metastasis 
(43%), and multifocality (49%).  
 
Death-associated protein kinase (DAPK) 
DAPK is a calcium/calmodulin-dependent serine threonine kinase protein with a 
pro-apoptotic, tumor suppressor function43,48. The DAPK gene is silenced by 
hypermethylated in several human cancers43,49,50, including thyroid cancer, and its 
expression has been shown to be a useful marker for cancer prognosis48. In addition to 
aberrant DNA methylation, chromatin immunoprecipitation analysis demonstrated that 
histone deacetylation of the 5' CpG island is involved in gastrointestinal malignancies49. 
In papillary thyroid cancer, promoter hypermethylation of DAPK was demonstrated in 




Retinoic acid receptor-β2 (RARβ2) 
RARβ2 plays a central role in the regulation of epithelial cells growth and 
tumorigenesis. Effects of retinoids are mediated by nuclear receptors, RAR-α, RAR-β, 
and RAR-γ, RXR-α, RXR-β, and RXR-γ which form RXR-RAR heterodimers, which 
bind to specific DNA sequences, called RAR elements. It is thought that decreased 
expression of RARs may lead to resistance to retinoid effects51. Hypermethylation of 
RARβ2 was demonstrated in 22% of papillary thyroid cancer, and was not associated 
with any aggressive clinicopathologic features43. 
 
Role of the Ras association domain family 1 isoform A (RASSF1A) in tumorigenesis 
The Ras association domain family 1 isoform A (RASSF1A) is one of 3 
transcripts of the RASSF1 gene on chromosome 3p21.3, derived from alternative 
splicing52. Activation of this tumor suppressor gene is implicated in a number of sporadic 
cancers. Rassf1A is thought to be an effector of RAS oncoproteins due to its RAS 
association domain and is involved in regulation of cell cycle progression, apoptosis, and 
microtubule stability.   
Rassf1A functions as a negative regulator of cell proliferation as evidenced by 
point mutations that inhibit tumor cell growth53-56. Rassf1A inhibits G1/S-phase 
progression; re-expression of RASSF1A in lung and breast tumor-derived epithelial cells 
results in growth arrest but not apoptosis55, which correlates with inhibition of cyclin D1 
accumulation and subsequent loss of arrest at the RB family cell cycle restriction point, 
allowing progression to S phase. Regulation of cyclin D1 accumulation by Rassf1A is 
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independent of the cyclin D1 promoter and occurs through inhibition of mRNA 
translation55.  
Rassf1A is thought to play a role as a scaffolding protein that assembles effector 
protein complexes. The death receptor stimulation results in the formation of a complex 
between Rassf1A and a microtubule-association protein, MAP1. In the absence of 
Rassf1A, MAP1 exists in an inactive closed conformation in inhibiting its interaction 
with BAX, a member of the BCL2 family and an important component of apoptotic 
machinery57,58. RassfF1A/MAP1 interaction is enhanced by activate K-Ras and is 
required for conformational change in BAX, mitochondrial membrane insertion, and 
maximal apoptosis in response to death receptor stimulation. Rassf1A and MAP1 are also 
recruited to the TNF-alpha and TRAIL receptor apoptosis complexes in response to their 
respective cognate ligands 59. Ectopic expression of Rassf1A enhances apoptosis in breast 
cancer cells, and knockout by RNA interference in osteosarcoma and breast cancer cells 
or by gene deletion in Rassf1a-null mouse embryonic fibroblasts specifically impairs 
death receptor-dependent apoptosis59-61. 
Another scaffolding role for Rassf1A involves stabilization of microtubules, 
modulated by microtubule-associated proteins (MAPs). MAPs bind directly to tubulin, 
and have also been shown to bind directly to Rassf1A60,62. This modulation of tubulin 
dynamics may involve Rassf1A in cell motility.  Overexpression of Rassf1A inhibits cell 
migration, and Rassf1A knockout reduces cell-to-cell adhesion 61. 
Rassf1A is a mitosis-specific inhibitor of the APC/C (anaphase-promoting 
complex/cyclosome), a large multisubunit complex that collaborates with ubiquitin-
conjugating and ubiquitin-activating enzymes. Ubiquitin-activating enzymes catalyze the 
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formation of polyubiquitin chains on its protein substrates that targets them for 
proteasome degradation 60. The activity of APC/C is thought to be restricted to a specific 
period in the cell cycle by the spatiotemporal regulation of mitosis by Rassf1A63. 
Rassf1A interacts with Cdc20 and inhibits the APC, preventing degradation of cyclin A 
and cyclin B until the spindle checkpoint becomes fully operational63. 
The RASSF1A locus is genetically and epigenetically inactivated at high 















Figure 2. Pathways involving RASSF1A65. RASSF1A regulates mitosis, the cell cycle 
and apoptosis in response to mitogenic or apoptotic stimuli. Direct interaction between 
RASSF1A and microtubule-associated proteins localizes RASSF1A to the microtubules, 
stabilizing them and, thereby, regulating mitosis. Repression of cyclins A and D1 by 
RASSF1A results in cell cycle arrest and interactions with CNK1, MST1, Salvador and 
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Table 1. Frequency of RASSF1A promoter hypermethylation in various tumor types65.  
Tumor type Frequency of hypermethylation 
Lung (SCLC) 88% 
Lung (NSCLC) 15 – 39% 
Breast 81 – 95 % 
Colorectal 20 – 52% 
Prostate 99% 
Cervical Adenocarcinoma 45% 
Esophageal 34% 
Gastric 44% 
Renal 56 – 915 
Hepatocellular  75% 
Bladder 30 – 50% 
Pancreatic 63% 
Ovarian 26 – 30% 
Nasopharyngeal 68% 
Leukemia 0 – 15% 
Neuroblastoma 83% 
Thyroid 35 – 71% 
Cholangiocarcinoma 67% 
Ependymoma 36 – 86% 
Glioma 54 – 57% 





Testicular (Seminoma) 40% 
Tesicular (Non-seminoma) 83% 
Wilm’s tumor 54% 
Rhabdomyosarcoma 61% 
Pheochromocytoma 22% 








HYPOTHESIS AND SPECIFIC AIMS 
 
We hypothesize that characterization of the PTC “methylome” is likely to provide 
insights into the molecular pathogenesis of PTC and lay the basis for prevention, 
improved diagnosis, and classification of thyroid cancer and provide critical insights for 
individualized medical and surgical treatment of these patients. We aim to  
1. Characterize the PTC “methylome” in a discovery cohort of clinically well-
characterized patients with both early (Stage I, T1 N0) and late stage PTC (Stage 
III-IV, T3-4, N1b, M1) via quantitative whole genome DNA methylation analysis 
in a “discovery set” of human PTC.  
2. Analyze hypermethylation, gene silencing and function of selected genes 
identified during the discovery phase in a larger “verification set” of human PTC. 
This approach is likely to identify not only genes showing frequent alterations in 
methylation patterns in PTC, but also genes and pathways altered in aggressive metastatic 
PTC. Additional studies will be performed in a larger verification cohort of PTC as well 




MATERIAL AND METHODS 
 
Subjects and Tissues (performed by thesis author) 
Papillary thyroid carcinomas (n=50) were acquired from patients diagnosed and 
surgically treated in the clinical routine at Yale-New Haven Hospital and clinical 
characteristics are presented in Table 1. All tumors were carefully evaluated and 
dissected by an experienced endocrine pathologist prior to use in the study and the 
diagnosis of papillary thyroid carcinoma was unequivocal. Tissues were snap-frozen in 
OCT using liquid nitrogen and stored in -80ºC. Informed consent and approval by the 
institutional review board was obtained.  
 
DNA and RNA isolation and Gene sequencing 
High molecular weight genomic DNA was isolated from normal and neoplastic thyroid 
tissue as previously described66 and gene sequencing was performed by the Yale Keck 
Facility and analyzed using Genome Studio CodonCode Aligner. 
 
Bisulfite modification of DNA (performed by thesis author) 
Genomic DNA (500ng) was bisulphite modified using the EZ DNA Methylation kit 






Genome-wide DNA methylation profiling (performed by the principal investigator and 
lab residents) 
Bisulfite-modified DNA was analyzed using Infinium HumanMethylation27 
BeadChip (Illumina, San Diego, CA). The Infinium HumanMethylation27 BeadChip 
protocol comprises six steps (whole-genome amplification, fragmentation, hybridization, 
washing, counterstaining and scanning)67, which were carried out at the Yale Center for 
Genome Analysis at Yale University according to the manufacturer’s recommendation. 
Details can be found at 
http://www.illumina.com/downloads/InfMethylation_AppNote.pdf. The Infinium 
HumanMethylation27 BeadChip is a novel genome-wide DNA methylation platform that 
allows interrogation of 27,578 highly informative CpG sites per sample at single-
nucleotide resolution68,69. The 12-sample Bead Chip features content derived from the 
NCBI CCDS database (Genome Build 36) and is supplemented with more than 1,000 
cancer-related genes68,69.  
 
Methylation-specific Real-time PCR (MSP) analysis using SYBR Green (performed 
by thesis author) 
To verify the findings from the methylation arrays, selected genes were analyzed 
using MS-PCR. Methylation-specific primers (table 2) were designed using the Methyl 
Primer Express software. MethPrimer is based on Primer 3 software and searches an 
input DNA sequence for potential CpGislands then designs MSP primers around those 
sites. Semiquantitative PCR was performed on Bio-Rad systems Real-Time PCR systems 
(Bio Rad Laboratories Inc. Hercules, CA, USA) using SYBR-Green PCR Master Mix 
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(#4309155) and results were analyzed using StepOne Software v2.1 (Applied 
Biosystems, Foster City, CA, USA). Commercial methylated, unmethylated, and 
genomic DNA were used as MSP assay controls and for determining the cut-off for 
hypermethylation. Percent methylation was calculated using the formula 100/[1+2^(Ct 
Meth – Ct UnMeth)1] 
 
Table 2. Primers used for methylation-specific real-time PCR analysis of gene expression 
CpG Island Forward primer Reverse primer 
RASSF1A-CpG#1-M tttcgaagggtgaggtattc ctcctatctcgaaacgctct 
RASSF1A-CpG#1-UM gggttttgaagggtgaggtattt atactcctatctcaaaacactct 
RASSF1A-CpG#2-M agaaatacgggtattttcgc acgaaactaaacgcgctc 
RASSF1A-CpG#2-UM tttagaaatatgggtatttttgt aaacaaaactaaacacactct 
CDKN2B/p15-CpG#1-M attatagcggatagggggc cgcctcgctctaacaaaat 
CDKN2B/p15-CpG#1-UM gattatagtggatagggggt ccacctcactctaacaaaat 
CDKN2B/p15-CpG#2-M gggttttagggtttcgtc cgcgtaaaatacacacct 
CDKN2B/p15-CpG#2-UM tggggttttagggttttgtt tacacataaaatacacacct 
 
 
                                                
1 Ct Meth and Ct UnMeth are the threshold cycles of methylated DNA and unmethylated 
DNA from the MSP reaction. 
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Quantitative RT-PCR analysis (performed by thesis author).  
Complementary DNA (cDNA) was synthesized using 1 µg of total RNA and 
iScript cDNA Synthesis Kit (Bio-Rad Laboratories Inc. Hercules, CA, USA). Primers 
(table 3) were designed with Primer3Plus software or obtained from the NCI QPCR 
primer database.  Quantitative real-time PCR was performed on Bio-Rad systems Real-
Time PCR systems (Bio Rad Laboratories Inc. Hercules, CA, USA) using assays for 
CDKN2B, RASSF1A, and GAPDH (All from Applied Biosystems, Foster City, CA). 




Table 3. Primers used for quantitative real-time PCR analysis of gene expression. 
 
Gene Forward primer Reverse primer 
RASSF1A tgggagacacctgacctttc tgggcaggtaaaaggaagtg 
GAPDH aaggtgaaggtcggagtcaa aatgaaggggtcattgatgg 
 
 
Statistical analysis (performed by the principal investigator, lab resident, and thesis 
author). The BeadChip was scanned on the Illlumina iScan and the resulting files were 
analyzed with the Beadstudio software (Version 3.2; Illumina). The output of the 
Beadstudio analysis is a beta-value for each CpG site interrogated. This is a continuous 
value between 0 and 1 where 0 indicates 0% methylation and 1 indicates 100% 
methylation at a given CpG site. Therefore, this assay provides quantitative methylation 
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measurement at the single CpG site level. The calculation of the beta-value is performed 
as described67. Wilcoxon rank test, Student's unpaired t-test, and Fisher exact test were 
used for statistical evaluation, with p<0.05 considered to be significant. All results are 







Hierarchical clustering of genes with altered DNA methylation profiles in 
papillary thyroid cancer did not show any relationship to age, gender, tumor size, lymph 
node status, pathological or clinical TNM stage. However, a distinct DNA methylation 
profile was noted in BRAF V600E PTC versus BRAF WT PTC, with 24 genes 
displaying significant hypermethylation in BRAF V600E PTC versus BRAF WT 
(p<0.005) (table 4). These included genes involved in transcriptional regulation and cell 
cycle control such as CDKN2B/p15 and RASSF1A.  
BRAF mutational status was determined by Sanger sequencing of papillary 
thyroid tumors (figure 3). Twenty-five BRAF V600E PTC and BRAF WT PTC (table 5) 
were selected for validation of the methylation profile of RASSF1 and analysis of its 
gene expression. Tumors in the BRAF V600E cohort had the characteristic aggressive 
phenotypes expected. Extrathyroidal extension, lymphovascular invasion, and lymph 
node involvement was observed in 34% (p < 0.005), 22% (p < 0.005), and 48% (p < 
0.0005) of tumors in the BRAF V600E cohort versus BRAF WT, respectively (table 5). 
In addition, tumors in the BRAF V600E cohort presented at a higher AJCC stage. 59% of 
BRAF V600E tumors were AJCC stage III-IV compared to 5% of the BRAF WT tumors 
(p < 0.005). No significant difference in patient age or tumor size was observed.  
Hypermethylation observed on the Infinium HumanMethylation27 BeadChip 
methylation array was validated by methylation-specific quantitative PCR (MS-PCR). 
One of two CpG islands (CpG#1) in the Rassf1A promoter was equally hypermethylated 
in BRAF V600E PTC and BRAF WT PTC, with an average of 39% and 38% 
respectively (figure 4). The second CpG island (CpG#2) was differentially methylated 
 
 34 
with an average of 73% and 8% (p<0.0005) methylation in BRAF V600E PTC and 
BRAF WT PTC respectively (figure 5). Commercially available fully methylated, fully 
unmethylated, and genomic DNA used as methylation controls, showed 96%, 1%, and 
18% methylation of the Rassf1A promoter respectively (figure 6A).Ninety-two % (n=23) 
of the BRAF V600E tumors were hypermethylated at CpG#2, compared to 12% (n=3) of 
the BRAF WT tumors (figure 4A).  
Two-step quantitative PCR was performed on RNA isolated from all tumors in 
both cohorts. Gene expression was quantified and Rassf1A expression was normalized to 
Gapdh. The efficiency of both primers were determined using a standard curve. 
Normalized Rassf1A expression from each BRAF V600E tumor was compared to the 
average expression in the BRAF WT cohort. Expression of Rassf1A was decreased 0.64-
fold in BRAF V600E PTC relative to expression in BRAF WT PTC (p<0.05).  
Promoter hypermethylation of CDKN2B/p15 was also addressed. Two CpG 
islands were assessed in the 5’-UTR and intron 1, and neither of these CpG islands were 
hypermethylated in PTC. 99% and 0% methylation of the CDKN2B/p15 promoter was 
seen in the methylated and unmethylated DNA controls, with some variation in the 
genomic controls. The 5‘UTR CpG island showed 8% methylation while the CpG island 
in intron 1 showed 34% methylation. The average methylation seen in the PTC cohorts at 





















FAM113B Hypothetical protein LOC91523 0.61 0.41 0.20 
CD6 CD6 antigen 0.79 0.59 0.20 
FLJ45909 Hypothetical protein LOC126432 0.61 0.41 0.20 
PTPN7 
Protein tyrosine phosphatase; non-receptor type 7 
isoform 1 0.70 0.50 0.20 
CDKN2B Cyclin-dependent kinase inhibitor 2B 0.52 0.32 0.20 
KLHL6 Kelch-like 6 0.62 0.41 0.20 
MS4A1 
Membrane-spanning 4-domains; subfamily A; 
member 1 0.70 0.50 0.20 
SEMA3B Semaphorin 3B isoform 1 precursor 0.72 0.51 0.20 
SLAMF8 B lymphocyte activator macrophage expressed 0.56 0.36 0.20 
LGP2 Hypothetical protein LOC79132 0.33 0.12 0.20 
CD5 CD5 antigen (p56-62) 0.80 0.59 0.21 
RASSF1 Ras association domain family 1 isoform A 0.55 0.34 0.21 
C16orf54 Chromosome 16 open reading frame 54 0.69 0.49 0.21 
CDH5 Cadherin 5; type 2 preproprotein 0.64 0.43 0.21 
ACY3 Aspartoacylase (aminocyclase) 3 0.53 0.33 0.21 
LAPTM5 Lysosomal associated multispanning membrane 0.55 0.34 0.21 
                                                
2 The beta-value or methylation index (MI) for each CpG site corresponds to the ratio of 
the fluorescence signal from the methylated allele (C) to the sum of the fluorescent 
signals of the methylated (C) and unmethylated (T) alleles75. The methylation status for 
each detected CpG site ranges between 0.1 (completely unmethylated) to 1 (completely 
methylated). Genes with a delta beta value ≥ 0.20 (difference between the methylation 




LTA Lymphotoxin alpha precursor 0.72 0.51 0.21 
CREB3L3 cAMP responsive element binding protein 3-like 3 0.39 0.18 0.21 
PPP1R16B 
Protein phosphatase 1 regulatory inhibitor subunit 
16B 0.58 0.37 0.21 
LSP1 Lymphocyte-specific protein 1 isoform 1 0.74 0.53 0.21 
ZBTB32 Testis zinc finger protein 0.81 0.60 0.21 
LAT Linker for activation of T cells isoform a 0.68 0.47 0.21 
LIMD2 Hypothetical protein LOC80774 0.61 0.40 0.22 
LY9 Lymphocyte antigen 9 isoform a 0.67 0.45 0.22 
RASSF1 Ras association domain family 1 isoform A 0.54 0.32 0.22 
VCY Variable charge; Y-linked 0.73 0.51 0.22 
CD79B CD79B antigen isoform 1 precursor 0.63 0.41 0.22 
FLJ33860 Hypothetical protein LOC284756 0.62 0.40 0.22 
TMC8 EVIN2 0.76 0.53 0.23 
C16orf54 Chromosome 16 open reading frame 54 0.78 0.55 0.23 
C17orf62 Chromosome 17 open reading fram 62 0.64 0.40 0.23 
RASSF1 Ras association domain family 1 isoform A 0.59 0.36 0.23 
GPR114 G-protein coupled receptor 114 0.61 0.37 0.24 
CD6 CD6 antigen 0.79 0.55 0.24 
RASSF1 Ras association domain family 1 isoform A 0.61 0.37 0.24 





















               
 
Figure 3. Sanger sequencing of the BRAF T1799A mutation. Left: Homozygous 
















Table 5. Twenty-five BRAF V600E PTC and BRAF WT PTC were used for validation 
of the methylation profile of RASSF1 and analysis of its gene expression. *p < 0.05;  
**p < 0.005; ***p < 0.0005 
 
Clinicopathologic characteristics BRAF V600E PTC BRAF WT PTC 
Age (yrs) 47 50 
Tumor size (cm) 1.88 1.24 
Classical variant (%)** 91 50 
Follicular variant (%)** 9 50 
Unifocal (%) 22 20 
Multicfocal (%)* 65 40 
Extrathyroidal extension (%)** 34 0 
Lymphovascular invasion (%)** 22 0 
Lymph node metastasis (%)*** 48 0 
AJCC Stage I – II (%)** 41 95 
















Figure 4. CpG island #1 of the RASSF1A promoter was equally hypermethylated in 
BRAF V600E PTC (mutated) and BRAF WT PTC (wildtype). A. An average of 38% and 
39% methylation was observed in the mutated and wildtype samples respectively. B. 
Methylation percentage of CpG island #1 for each individual tumor in the cohorts. Red 












Figure 5. CpG #2 of the RASSF1A promoter was differentially methylated in BRAF 
V600E PTC (mutated) and BRAF WT PTC (wildtype). A. An average of 73% and 8% 
methylation was observed in the mutated and wildtype samples respectively. B. Shows 
the methylation percentage of CpG #2 for each individual tumor in the cohorts. Red dots 
















Figure 6. 92% (n=23) of the BRAF V600E tumors were hypermethylated at this CpG 
island, compared to 12% (n=3) of the BRAF WT tumors. A. Percentage of BRAF V600E 
(mutated) PTC and BRAF WT (wildtype) PTC hypermethylated.  B. Shows the 
methylation percentages of commercially available control DNA. Meth = fully 
methylated DNA; Unmeth = fully unmethylated DNA; Genomic = genomic DNA. 












Figure 7. Relative expression of RASSF1A was determined by quantitative QPCR 
analysis, normalized to GAPDH.  A. RASSF1A expression was decreased in BRAF 
V600E PTC relative to expression in BRAF WT PTC (p<0.05). B. RASSF1A expression 
of individual samples in the BRAF V600E PTC cohort relative to the mean expression of 







The DNA methylation profile of PTC correlates with BRAF mutational status, 
underscoring its importance in PTC development. Twenty-four genes were significantly 
hypermethylated in BRAF V600E versus BRAF WT PTC, including genes involved in 
transcriptional control and cell cycle regulation. One of two CpG islands in the 
RASSF1A promoter was hypermethylated in 92% of BRAF V600E PTC, with an 
average of 72% methylation, compared to 12% of BRAF WT PTC (8% average 
methylation). Hypermethylation of this CpG island appears to correlate with reduced 
RASSF1A mRNA levels in BRAF V600E PTC. No other clinical or pathological 
characteristics correlated with the DNA methylation profile of PTC on the genome-wide 
DNA methylation array performed. 
The molecular mechanism of the more aggressive phenotype of BRAF V600E 
PTC may be related to aberrant DNA methylation of genes involved in transcriptional 
and cell cycle control. Functional studies assessing the effect of this hypermethylation on 
RASSF1A gene expression may further determine a cause-effect relationship. In addition 
to the mRNA analysis performed, protein expression analysis using 
immunohistochemistry and western blot analysis on PTC tissue would detect any changes 
in RASSF1A expression in BRAF V600E PTC compared to expression in wildtype 
tumors. Furthermore, assessing the effect of azanucleoside, a demethylating agent, on 
RASSF1A gene expression in PTC cell cultures may further determine a cause-effect 
relation, and would be critical in assessing the possibility of clinically applying a 
demethylating agent to treatment of aggressive, BRAF V600E PTC. 
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With improved diagnostic techniques, endocrine tumors are identified much more 
frequently than in the past. For instance, benign parathyroid tumors occurs in as many as 
2.3% of postmenopausal women70, and primary hyperaldosteronism may be the cause of 
hypertension in as many as 4.8% of all patients with elevated blood pressure71. The 
molecular genetics of rare inherited endocrine tumor susceptibility syndromes, such as 
multiple endocrine neoplasia (MEN) type 1 and 2, familial pheochromocytoma 
syndromes, Carney Complex, and Beckwith-Wiedemann syndrome have all contributed 
to our understanding of endocrine tumor development72,73. Among different tumor types, 
there exist common pathways that lead to tumorigenesis, such as inactivation of the 
MEN1 tumor suppressor and activation of the RET proto-oncogene. As in other cancers, 
it is believed that the vast majority of genetic changes are somatic, i.e. tumor specific 
mutations acquired during tumor progression74. 
Epigenetic mechanisms, especially aberrant DNA methylation, very likely play an 
important role in papillary thyroid tumorigenesis. Genome-wide DNA methylation 
studies in PTC provide a powerful tool to identify disease-causing genes. Additionally, 
unbiased, systematic analyses of tumor methylomes are likely to identify signaling 
pathways of importance in cancer development, in general. Analyzing epigenetic 
alterations in papillary thyroid cancer would help to characterize pathogenesis and may 
play a critical role in tumor classification and diagnosis. It has recently been shown that 
there differences in global methylation profiles between prognostic subsets of chronic 
lymphocytic leukemia (CLL)75. The specific silencing of unmethylated tumor suppressor 
genes was seen in the unmutated IGHV subgroup of CLL, implying a critical role for 
epigenetic changes during leukemogenesis. Interestingly, patients with immunoglobulin 
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heavy-chain variable gene (IGHV) unmutated CLL have worse prognoses compared to 
CLL patients with mutated IGHV genes75. 
 These studies may also pave the way for the application of epigenetic 
therapeutics, by targeted reversal of gene silencing. Azanucleoside drugs are 
demethylating agents that are currently approved for treatment of myelodyspastic 
syndrome19,72. These function as DNA methyltransferase enzymes, require incorporation 
into DNA to be effective, and affect the differentiated state. Other nucleoside DNA 
methylation inhibitors include 5-fluoro-2’-deoxycytidine and zebulamine76 which are in 
development. Histone deacetylases77,78 and histone methyltransferases are another 
reasonable option for therapeutics. The histone deacetylase SAHA is currently approved 
by the FDA for treatment of T cell lymphoma79.  
Just as multiple epigenetic events may act in concert to affect a single-cell 
pathway, it is most likely that epigenetic therapy will involve using multiple drugs that 
individually affect epigenetic silencing but have synergistic effects. Proposed strategies 
for the FDA approved epigenetic drugs are as single therapies or in combination as 
primary or secondary treatment after neo-adjuvant chemotherapy. Lack of specificity 
may not pose a problem since DNMT inhibitors act only on dividing cells. The drugs 
preferentially activate genes that have become abnormally silenced in cancer80. 
Moreover, the chromatin structure associated with a pathologically silenced gene may be 
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